E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Locally advanced or metastatic medullary thyroid cancer |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10027105 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate a decrease in the percentage of time patients with locally advanced or metastatic medullary thyroid cancer experience adverse events of CTCAE grade 2 or higher in the first 12 months of receiving vandetanib with the use of a patient outreach program. |
|
E.2.2 | Secondary objectives of the trial |
To collect additional information on the safety and tolerability of vandetanib in patients with locally advanced or metastatic medullary thyroid cancer. The exploratory objective of this study is to investigate patient health status index during the first 12 months of treatment with vandetanib by assessment of the EuroQoL 5 Dimension Instrument (EQ-5D) in patients with locally advanced or metastatic medullary thyroid cancer. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Provision of informed consent prior to any study specific procedures 2.Female or male aged 18 years and over 3.Previously confirmed histological diagnosis of unresectable, locally advanced or metastatic hereditary or sporadic MTC. Documentation must be provided in patient’s medical chart. 4.WHO or ECOG Performance status 0-2 5.Negative pregnancy test (urine or serum) for female patients of childbearing potential |
|
E.4 | Principal exclusion criteria |
1. Brain metastases or spinal cord compression, unless treated at least 4 weeks before first dose and stable without steroid treatment for 10 days 2. Major surgery within 4 weeks before randomization 3. The last dose of prior chemotherapy received less than 3 weeks prior to randomization 4. Radiation therapy not completed prior to the first dose of vandetanib 5. Any unresolved chronic toxicity greater than CTCAE grade 2 from previous anticancer therapy (this criterion does not apply to alopecia) 6. Serum bilirubin greater than 1.5 x the upper limit of reference range (ULRR), this criterion does not apply to patients with Gilbert’s Disease 7. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) greater than 2.5 x ULRR, or greater than 5.0 x ULRR if judged by the investigator to be related to liver metastases 8. Creatinine clearance <30 ml/min (calculated by Cockcroft-Gault formula, reference in Appendix G) 9. Potassium <4.0 mmol/L despite supplementation, or above the CTCAE grade 1 upper limit. Magnesium below the normal range despite supplementation, or above the CTCAE grade 1 upper limit. Calcium can be evaluated by either ionized or standard serum tests. Ionized calcium values below the normal range or above the CTCAE grade 1 upper limit. If serum calcium is used, exclusion for values above the CTCAE grade 1 upper limit. In cases where the serum calcium is below the normal range, the calcium adjusted for albumin is to be obtained and substituted for the measured serum value. Exclusion is to then be based on the calcium adjusted for albumin values falling below the normal limit. Corrected Calcium=Ca + 0.8 X (4-serum albumin) 10. Significant cardiac event (eg myocardial infarction), superior vena cava (SVC) syndrome, New York Heart Association (NYHA) classification of heart disease ≥2 (reference Appendix H), within 12 weeks before randomization, or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia 11. History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment (CTCAE grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Patients with atrial fibrillation controlled by medication are permitted. 12. Congenital long QT syndrome 13. Any concomitant medications that are known to be associated with Torsades de Pointes (reference Appendix E, Table 1) or potent inducers of CYP3A4 function and/or any prohibited medications referenced in Section 5.6 14. History of QT prolongation associated with other medications that required discontinuation of that medication 15. QTc with Bazett’s correction unmeasurable or ≥480 ms on screening ECG (Note: If a patient has QTc interval ≥480 ms on screening ECG, the screening ECG may be repeated 2 times [at least 24 hours apart] for a total of 3 ECGs. The average QTc from the three screening ECGs must be <480 ms in order for the patient to be eligible for the study). |
|
E.5 End points |
E.5.1 | Primary end point(s) | |
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 26 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Questo studio sara` chiuso in ciascun paese in seguito all` autorizzazione AIC. I pazienti gia` arruolati nello studio nel paese che riceve AIC, continueraano lo studio ma nessun nuovo paziente potra` essere arruolato |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |